Midostaurin may have the potential to enhance immunotherapy in clinical practice by activating STING pathway.Midostaurin inhibited the growth of colorectal adenocarcinoma cells in a dose- and time-dependent way, which was associated with the formation of cytosolic DNA and activation of the cGAS-STING pathway. Oral administration midostaurin combined with anti-PD-1 enhanced anti-PD-1 efficacy by increasing STING and IFNβ expression of the tumors. The gene discussed is PDCD1; the disease is colorectal adenocarcinoma.